CCR Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 31 clinical trials at NIH that match your search criteria

Cancer by body location/system: Digestive/ Gastrointestinal

Trial and Protocol Number Anal Cancer	Principal Investigator	Referral Contact
A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers NCI-12-C-0116, NCT01585428	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	June A. Kryk 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
A Pilot Trial Assessing the Feasibility of Delivering Topical MTS-01 to Reduce Dermatitis in Patients Receiving Intensity Modulated Radiation With Concurrent 5-Fluorouracil and Mitomycin-C for Stage I-III Carcinoma of the Anal Canal NCI-11-C-0129, NCT01324141	Deborah E. Citrin 301-496-5457	Debbie McNally 301-451-8904 cooleyd@mail.nih.gov

Trial and Protocol Number Colorectal Cancer	Principal Investigator	Referral Contact
A Phase I, Open-label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C, a Monoclonal Anti-PD-L1 Antibody, in Adults With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications NCI-13-C-0063, NCT01772004	James L. Gulley 301-435-2956	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/neu ECTM in Adults With Tumors With 1-3+ HER2/neu Expression NCI-13-C-0016, NCT01730118	Lauren V. Wood 301-402-0199	Brenda Roberson 301-435-4733 broberson@mail.nih.gov
A Phase I/II Study of ISIS 183750 in Combination With Irinotecan in Irinotecan-refractory Colorectal Cancer NCI-12-C-0187 , NCT01675128	Tim F. Greten 301-451-4723	Suzanne Fioravanti 301-594-6544 fioravas@mail.nih.gov
An Open Label Phase I Study to Evaluate the Safety and Tolerability of GI-6301 Vaccine Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express Brachyury Protein in Adults With Solid Tumors NCI-12-C-0056, NCT01519817	James L. Gulley 301-435-2956	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7 in Older Subjects Following Chemotherapy NCI-11-C-0146, NCT01339000	Claude Sportès 301-435-5280	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov
Pilot Study of the Combination of MK-2206, an AKT Inhibitor, and AZD6244, a MEK Inhibitor, in Patients With Advanced Colorectal Carcinoma NCI-11-C-0117, NCT01333475	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid Tumors NCI-11-C-0061, NCT01273168	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors NCI-10-C-0113, NCT01120288	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase II Study of BAY 43-9006 (Sorafenib) in Combination With Cetuximab (Erbitux^®) in EGFR Expressing Metastatic Colorectal Cancer (CRC) NCI-06-C-0164, NCT00326495	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov

Trial and Protocol Number Esophageal Cancer	Principal Investigator	Referral Contact
Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum NCI-12-C-0151, NCT01624090	David S. Schrump 301-496-2128	Tricia Kunst 301-451-1233 tricia_kunst@nih.gov
Adjuvant Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura, or Mediastinum NCI-11-C-0111, NCT01313429	David S. Schrump 301-496-2128	Tricia Kunst 301-451-1233 tricia_kunst@nih.gov
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas NCI-10-C-0138, NCT01143545	David S. Schrump 301-496-2128	Tricia Kunst 301-451-1233 tricia_kunst@nih.gov
A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies NCI-07-C-0111, NCT00452946	Deborah E. Citrin 301-496-5457	Sharon L. Smith 301-496-5457 smiths@mail.nih.gov
Prospective Evaluation of Epigenetic Alterations in Patients With Thoracic Malignancies NCI-06-C-0014, NCT00447447	David S. Schrump 301-496-2128	Tricia Kunst 301-451-1233 tricia_kunst@nih.gov

Trial and Protocol Number Gastrointestinal Stromal Tumor (GIST)	Principal Investigator	Referral Contact
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors NCI-09-C-0019, NCT01445509	Elise C. Kohn 301-402-2726	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov

Trial and Protocol Number Liver Cancer	Principal Investigator	Referral Contact
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma NCI-12-C-0098, NCT01502410	Brigitte Widemann 301-496-7387	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)
A Phase II Study of TRC105 in Patients With Hepatocellular Carcinoma (HCC) Who Have Progressed on Sorafenib NCI-11-C-0181, NCT01375569	Tim F. Greten 301-451-4723	Suzanne Fioravanti 301-594-6544 fioravas@mail.nih.gov
A Phase I/II Study of TRC105 in Combination With Sorafenib in Hepatocellular Carcinoma (HCC) NCI-11-C-0102, NCT01306058	Tim F. Greten 301-451-4723	Suzanne Fioravanti 301-594-6544 fioravas@mail.nih.gov

Trial and Protocol Number Pancreatic Cancer	Principal Investigator	Referral Contact
A Phase I/II Trial of IL-13-PE in Patients with Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma NCI-13-C-0046, NCT01766635	Electron Kebebew 301-496-5049	Erinn M. Hopkins 301-496-6457 erinn.hopkins@nih.gov
A Phase I and Pharmacokinetic Single-agent Study of Romidepsin in Patients With Lymphomas, Chronic Lymphocytic Leukemia, Select Solid Tumors, and Varying Degrees of Liver Dysfunction NCI-12-C-0177, NCT01638533	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets NCI-12-C-0175, NCT01658917	Udai Kammula 301-435-8606	Carole Webb 301-402-8475 Webbcc@mail.nih.gov
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes NCI-12-C-0111, NCT01583686	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	June A. Kryk 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Anti-mesothelin Antibody Drug Conjugate BAY94-9343 in Subjects With Advanced Solid Tumors NCI-12-C-0008, NCT01439152	Raffit Hassan 301-451-8742	Yvonne Mallory 301-402-0255 malloryy@mail.nih.gov
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers NCI-11-C-0212, NCT01413451	Raffit Hassan 301-451-8742	Yvonne Mallory 301-402-0255 malloryy@mail.nih.gov
Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial NCI-11-C-0099, NCT01294358	Udo Rudloff 301-496-3098	Melissa Walker 301-402-9537 walkerme@mail.nih.gov
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms NCI-09-C-0242, NCT01005654	Electron Kebebew 301-496-5049	Erinn M. Hopkins 301-496-6457 erinn.hopkins@nih.gov
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes NCI-08-C-0121, NCT00670748	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	June A. Kryk 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov

Trial and Protocol Number Stomach (Gastric) Cancer	Principal Investigator	Referral Contact
Phase Ib Study of the Combination of Pazopanib, an Oral VEGFR Inhibitor, and ARQ 197 (Tivantinib), an Oral MET Inhibitor, in Patients With Refractory Advanced Solid Tumors NCI-12-C-0009, NCT01468922	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase II Study Using Short-Term Cultured, CD8+-enriched Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Digestive Tract Cancers NCI-10-C-0166, NCT01174121	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	June A. Kryk 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov

For additional studies that may be appropriate for your disease type, please search under Solid Tumor.